Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

",II,"FEB / 17"
"Naloxone hydrochloride nasal spray,",,"

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

",II,"FEB / 17"
"Naloxone or its salts",PDL,"

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

",I,"FEB / 17"
"Naltrexone or its salts ",PDL,,I,"DEC / 13"
Nandrolone,C3,,I,"JUN / 02"
"Naphazoline and its salts",,"in nasal preparations for pediatric use",II,"SEP / 98"
"Naphazoline and its salts.",,"in nasal preparations for adult use and in ophthalmic products",U,
"Naproxen or its salts",,"

Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.

For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).

",I,"AUG / 18"
"Nicotine or its salts",PDL,"

For veterinary use.

",I,"DEC / 13"
"Nicotinic acid",PDL,"

For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.

",I,"DEC / 13"
Nusinersen,PDL,,I,"AUG / 17"
"Nylidrin or its salts",PDL,,I,"DEC / 13"
"Nystatin and its salts and derivatives.",,"in topical preparations for use on the skin",III,"SEP / 98"
"Nystatin or its salts or derivatives",PDL,"